PAVM
PAVmed Inc.
Set alert
- YTD
- -70.59%
- 1 year
- -84.63%
- Open
- 2.00
- Prev close
- 2.01
- Mkt cap
- 15.59M
- Vol
- 6.62K
- Avg vol
- 29.95K
- EPS
- -14.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.95
- High
- 2.08
- Forward P/E
- -0.45
- Beta
- 0.69
- Short ratio
- 9.07
- Inst. own
- 14.59%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.98348
- 200-d avg
- 1.31
- 1y target
- 9.00
Key statistics
- Market cap
- 7.14M
- Enterprise value
- 92.44M
- Trailing P/E
- 0.00
- Forward P/E
- -0.45
- PEG ratio
- 0.00
- Price / sales
- 1.86
- Price / book
- 0.00
- EPS (TTM)
- -1.14
- Beta
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.83M
- Revenue growth
- 489.80%
- Free cash flow
- -26.64M
- Total cash
- 27.39M
- Total debt
- 50.03M
- Return on equity
- 0.00%
- Shares outstanding
- 11.07M
- Short % of float
- 3.09%
- 50-day average
- 0.98348
- 200-day average
- 1.31
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 9.00
- Target (high)
- 19.00
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.30 | -0.54 | +0.76 | +58.46% |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.84 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.99 | — | — |
| Mar 26, 2024 | Dec 1, 2023 | 0.00 | -1.33 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -1.35 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | -1.35 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
About PAVmed Inc.
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- pavmed.com
News
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
- Contrasting PAVmed (NASDAQ:PAVM) and InMode (NASDAQ:INMD)
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Your note
Sign in to keep a note on PAVM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAXTER TIMOTHY E | Director | Stock Award(Grant) | Feb 21, 2024 | 65,000 |
| COX JAMES L | Director | Stock Award(Grant) | Feb 21, 2024 | 65,000 |
| GLENNON MICHAEL J | Director | Stock Award(Grant) | Feb 21, 2024 | 315,000 |
| HARVEY JOAN B. | Director | Stock Award(Grant) | Feb 21, 2024 | 65,000 |
| WHITE DEBRA JAYNE | Director | Stock Award(Grant) | Feb 21, 2024 | 65,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Manhattan Co. LLC | 5.42% | 600,000 | 387.00K | Sep 29, 2024 |
| Vanguard Group Inc | 2.54% | 281,015 | 181.25K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.75% | 82,496 | 53.21K | Sep 29, 2024 |
| Blackrock Inc. | 0.68% | 74,912 | 48.32K | Sep 29, 2024 |
| Obermeyer Wood Investment Counsel, Lllp | 0.19% | 21,500 | 13.87K | Sep 29, 2024 |
| State Street Corporation | 0.19% | 20,854 | 13.45K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.85% | 204,821 | 132.11K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 79,689 | 51.40K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 52,341 | 33.76K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 12,442 | 8.03K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 7,850 | 5.06K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,332 | 859 | Oct 30, 2024 |